NervGen Pharma Corp. (NGEN)Healthcare | Biotechnology | Vancouver, Canada | NasdaqCM
1.65 USD
+0.02
(1.543%)
⇧
(Oct. 16, 2026, 10:18 a.m.
EDT)
|
Hot Take ↕ | Oct. 10, 2026, 2:04 a.m. EDT
The investment case here is defined by a stark disconnect between aggressive analyst optimism and deteriorating corporate reality. While a single analyst maintains a 'strong buy' rating with a $10 target, the company's fundamentals tell a different story: negative earnings, negative return on equity, and a recent voluntary delisting from the TSX Venture Exchange. This delisting is a critical red flag, signaling that the company is struggling to meet listing standards, likely due to capitalization or governance issues, which severely undermines any long-term thesis. The stock has rallied significantly over the past few years, but this momentum is built on a foundation of losses and shrinking liquidity. The options market reflects this fragility; there is virtually no hedging activity, meaning the current price is exposed to immediate devaluation if the next catalyst fails to materialize. For investors, this is a high-risk speculative play on a binary outcome rather than a sound investment in a viable business. |
| Model | MAE |
|---|---|
| AutoARIMA ✓ | 0.168814 |
| AutoETS | 0.171035 |
| AutoTheta | 0.171082 |
| MSTL | 0.188094 |
Forecast horizon: 45 days | Selected: AutoARIMA
| Forecast Reliability | |
|---|---|
| Score | 28% |
| H-stat | 35.16 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.137 |
| Excess Kurtosis | -1.46 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Market Cap | 176,874,720 |
| Forward P/E | -4.86 |
| Beta | 0.82 |
| Website | https://nervgen.com |
As of Oct. 10, 2026, 2:04 a.m. EDT: Options activity is extremely thin and skewed entirely toward calls, with zero put volume recorded across all expirations. Speculators are positioning for upside via out-of-the-money strikes at $5.00, suggesting a speculative bet on a binary event or clinical milestone rather than a hedging strategy against downside risk. The lack of put protection indicates a 'naked' bullish sentiment, though the low open interest suggests this positioning is fragile and lacks broad institutional conviction.
| Attribute | Value |
|---|---|
| 52 Week Change | -0.4436813 |
| Address1 | 112-970 Burrard Street |
| Address2 | Unit 1290 |
| All Time High | 6.3 |
| All Time Low | 0.55 |
| Ask | 2.06 |
| Ask Size | 2 |
| Average Analyst Rating | 1.4 - Strong Buy |
| Average Daily Volume10 Day | 445,700 |
| Average Daily Volume3 Month | 514,831 |
| Average Volume | 514,831 |
| Average Volume10Days | 445,700 |
| Beta | 0.823 |
| Bid | 1.2 |
| Bid Size | 2 |
| Book Value | 0.11397186 |
| City | Vancouver |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | Canada |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 1.645 |
| Current Ratio | 1.232 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,790,726,400 |
| Day High | 1.655 |
| Day Low | 1.6 |
| Display Name | NervGen Pharma |
| Dividend Yield | 0.0 |
| Earnings Timestamp | 1,786,624,200 |
| Earnings Timestamp End | 1,795,437,000 |
| Earnings Timestamp Start | 1,795,437,000 |
| Ebitda | -32,247,372 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -2.71 |
| Enterprise Value | 87,396,968 |
| Eps Current Year | -0.492 |
| Eps Forward | -0.33867 |
| Eps Trailing Twelve Months | -0.57 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 15 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 1.946 |
| Fifty Day Average Change | -0.301 |
| Fifty Day Average Change Percent | -0.15467626 |
| Fifty Two Week Change Percent | -44.36813 |
| Fifty Two Week High | 6.3 |
| Fifty Two Week High Change | -4.655 |
| Fifty Two Week High Change Percent | -0.7388889 |
| Fifty Two Week Low | 1.55 |
| Fifty Two Week Low Change | 0.09500003 |
| Fifty Two Week Low Change Percent | 0.061290342 |
| Fifty Two Week Range | 1.55 - 6.3 |
| Financial Currency | CAD |
| First Trade Date Milliseconds | 1,554,298,200,000 |
| Float Shares | 95,297,310 |
| Forward Eps | -0.33867 |
| Forward P E | -4.857236 |
| Free Cashflow | 38,391,200 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 9 |
| Fullday Change | 0.024999976 |
| Fullday Change Percent | 1.5432084 |
| Fullday Price | 1.645 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.0 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.15626 |
| Held Percent Institutions | 0.112440005 |
| Implied Shares Outstanding | 107,522,633 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ipo Expected Date | 2,026-01-08 |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | NervGen Pharma Corp., a biotechnology company, engages in the discovery, development, and commercialization of pharmaceutical treatments to promote nervous system repair in settings of neurotrauma and neurologic disease. The company's lead product candidate is NVG-291 that is in Phase 1b/2a clinical trial for the treatment of spinal cord injuries (SCI), stroke, multiple sclerosis, and Alzheimer's disease; and NVG-300, which is in a preclinical model of ischemic stroke, amyotrophic lateral sclerosis, and confirmatory SCI study. NervGen Pharma Corp. has a licensing agreement with Case Western Reserve University to develop and commercialize a patented technology with therapeutic potential for spinal cord injury and other conditions associated with nerve damage. NervGen Pharma Corp. was incorporated in 2017 and is headquartered in Vancouver, Canada. |
| Long Name | NervGen Pharma Corp. |
| Market | us_market |
| Market Cap | 176,874,720 |
| Market State | REGULAR |
| Max Age | 86,400 |
| Message Board Id | finmb_577702483 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -61,957,708 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 210,744,360 |
| Number Of Analyst Opinions | 1 |
| Open | 1.63 |
| Operating Cashflow | -25,647,716 |
| Operating Margins | 0.0 |
| Phone | 778 731 1711 |
| Previous Close | 1.62 |
| Price Eps Current Year | -3.3434958 |
| Price Hint | 4 |
| Price To Book | 14.433387 |
| Profit Margins | 0.0 |
| Quick Ratio | 1.193 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.42857 |
| Region | US |
| Regular Market Change | 0.024999976 |
| Regular Market Change Percent | 1.5432084 |
| Regular Market Day High | 1.655 |
| Regular Market Day Low | 1.6 |
| Regular Market Day Range | 1.6 - 1.655 |
| Regular Market Open | 1.63 |
| Regular Market Previous Close | 1.62 |
| Regular Market Price | 1.645 |
| Regular Market Time | 1,792,160,327 |
| Regular Market Volume | 61,302 |
| Return On Assets | -0.37697 |
| Return On Equity | -7.57482 |
| Sand P52 Week Change | 0.16207206 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 107,522,633 |
| Shares Percent Shares Out | 0.0542 |
| Shares Short | 5,832,084 |
| Shares Short Previous Month Date | 1,788,134,400 |
| Shares Short Prior Month | 5,443,963 |
| Short Name | NervGen Pharma Corp. |
| Short Ratio | 10.82 |
| Source Interval | 15 |
| State | BC |
| Symbol | NGEN |
| Target High Price | 10.0 |
| Target Low Price | 10.0 |
| Target Mean Price | 10.0 |
| Target Median Price | 10.0 |
| Total Cash | 86,789,696 |
| Total Cash Per Share | 0.807 |
| Total Debt | 0 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -0.57 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 3.072925 |
| Two Hundred Day Average Change | -1.4279251 |
| Two Hundred Day Average Change Percent | -0.46467945 |
| Type Disp | Equity |
| Volume | 61,302 |
| Website | https://nervgen.com |
| Zip | V6Z 2R4 |